Cabaletta Bio, Inc. (CABA) Cash Flow Statement

The persistent gap between net loss and operating cash outflow suggests that the company's cash consumption is driven by fundamental operational spending, primarily on research and development. The OCF/NI ratio remaining below 1.0, even with significant non-cash SBC add-backs, implies that the underlying business is consuming cash at a rate slightly faster than the accounting loss, a trend that warrants monitoring for any acceleration.

The escalating FCF deficit is a direct consequence of expanding R&D expenditures in the absence of revenue, as noted in the prior income statement analysis. This trajectory indicates that the company is in a phase of intensified investment, which, while necessary for pipeline development, shortens the financial runway and increases reliance on external financing. The lack of any revenue to offset these costs makes the burn rate the primary metric for assessing near-term viability.

The large negative working capital change in Q1 2026, which contributed to a wider operating cash deficit, suggests potential timing issues in payables or inventory management, though the specific drivers are not detailed. For a pre-revenue company, these swings are likely driven by the timing of payments to vendors and accruals for clinical trial costs, rather than traditional inventory cycles, and they obscure the underlying operational cash burn rate.

The absence of any capital returns or strategic investments confirms that Cabaletta is in a pure investment phase, channeling all available capital into its R&D programs. This singular focus is typical for a clinical-stage biotech but underscores that the company's value creation is entirely dependent on the future success of its pipeline, with no current cash generation to support shareholder returns or diversification.